Ultimovacs is a small pharmaceutical company developing novel immunotherapy against cancer. Our leading product is UV1, a therapeutic cancer vaccine (TCV) directed against human telomerase (hTERT). The vaccine is a result of many years of pre-clinical and clinical research at the Norwegian Radium Hospital. UV1 is a synthetic peptide vaccine.
The peptides included in the vaccine is based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.
The company is currently performing three clinical trials with UV1. Two trials are documenting safety and the vaccines ability to activate the immune system against cancer cells expressing the hTERT fragments that are the components of the vaccine when given as a single treatment.
A third clinical trial is assessing safety and clinical outcomes when combining UV1 with ipilimumab in patients with malignant melanoma.
The major owners of Ultimovacs are Gjelsten Holding, The Norwegian Radium Hospital Research Foundation, Inven2 ,Canica AS, Sundt AS and Langøya Invest AS. The company is currently located in Oslo Science Park, Oslo, Norway, but will move to Oslo Cancer Cluster Innovation Park in July 2015. The company is an active member of Oslo Cancer Cluster.
Øyvind K. ArnesenChief Executive Officer
MD with 10+ years of clinical experience and 10+ years of experience from pharma industry with positions as Medical Director Norway (Bristol-Myers Squibb), Medical Director and Head of Clinical Operations Nordic countries in Boehringer Ingelheim. Member of The National Commission for the Investigation of Research Misconduct in Norway. Board member of the Norwegian Pharmaceutical Industry Association.
Audun TornesChief Operating Officer
Gustav GaudernackChief Scientific Officer
Professor and head of Unit for Immunotherapy at Radiumhospitalet from 1995 to 2011. Initiated over 20 clinical studies in cancer vaccination, including the first peptide vaccine study in cancer world wide (mutant RAS). Has more than 50 patents and 15 licenses of monoclonal antibodies, cancer vaccines and cancer diagnostics.